Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design

Overview of attention for article published in Gastroenterology, September 2020

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 49 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 327,132 followers.

@AnirudhBhandare Inflm biomarker end points R secondary, used only bcoz of potential ease of collection. PlZ read guideline - best end points in IBD. https://t.co/QEFZop7aPN https://t.co/w1IYmgKYRc Disclosure - I am a hepatologist. I dnt practice Gastro…

Glad to have contributed to #IOIBD1 initiative: Defining Endpoints and Biomarkers in #IBD: Moving the Needle Through #Clinicaltrial Trial Design ⁦@ibddocmaria⁩ ⁦@bruce_sands1⁩ ⁦⁦@doc_ibd⁩ https://t.co/87uwrFeaIi

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.